MEN1 and pancreatic neuroendocrine tumor: This revealed that approximatley 3% of these patients with MEN1-associated tumors, such as parathyroid adenomas, pituitary adenomas and pancreatic NETs in association with gonadal, adrenal, renal and thyroid tumors have CDNK1B mutations.